Paragon 28 Inc (FNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

GuruFocus News
4 min read

In This Article:

  • Global Revenue: $61 million, 19.6% reported growth, 19.7% constant currency growth.

  • US Revenue: $49.7 million, 17.6% reported growth.

  • International Revenue: $11.3 million, 29.4% reported growth, 29.6% constant currency growth.

  • Gross Margin: 75.0%, down from 77.3% in Q2 2023.

  • R&D Expense: $7.1 million, 11.6% of revenue.

  • SG&A Expense: $49.4 million, 81% of revenue, improved by 490 basis points.

  • Adjusted EBITDA: $3 million loss, improved by $2.4 million from Q2 2023.

  • Operating Cash Flow: Negative $10.2 million.

  • Total Liquidity: $97 million, including $47 million cash and $50 million credit facility.

  • Revenue Guidance for 2024: $249 million to $255 million, 15.1% to 17.8% growth.

Release Date: August 08, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Paragon 28 Inc (NYSE:FNA) reported strong global revenue growth of 19.6% in the second quarter of 2024, with significant contributions from both the US and international markets.

  • The company successfully expanded its surgeon customer base by 11% and increased its US producing sales rep roster by 13.1%, enhancing sales force productivity by 7%.

  • Paragon 28 Inc (NYSE:FNA) launched 12 new products in the first seven months of the year, including innovative solutions like the R3FLEX Stabilization System and SMART Bun-Yo-Matic, which are expected to drive future growth.

  • The company is implementing a comprehensive operational efficiency plan to improve cost control and preserve cash, aiming for EBITDA positivity in 2025 and cash flow positivity in 2026.

  • Paragon 28 Inc (NYSE:FNA) ended the second quarter with $97 million in total liquidity, providing a solid financial foundation for future growth initiatives.

Negative Points

  • The company identified errors in inventory calculations, leading to a restatement of financials for 2023 and Q1 2024, highlighting weaknesses in internal controls.

  • Gross profit margin decreased to 75.0% from 77.3% in the prior year, primarily due to higher supplier prices and increased non-cash expenses for excess and obsolete inventory.

  • Operating cash flow was negative $10.2 million for the second quarter, reflecting challenges in managing net working capital and inventory purchases.

  • Revenue guidance for the full year 2024 was narrowed, indicating a potential slowdown in growth compared to previous expectations, with concerns about macroeconomic conditions impacting the foot and ankle market.

  • The company is undergoing workforce reductions and executive compensation realignment as part of its operational efficiency plan, which may impact employee morale and retention.

Recommended Stories